Cargando…

Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy

BACKGROUND: Melanoma patients who have detectable serum soluble NKG2D ligands either at the baseline or post-treatment of PD1/PDL1 blockade exhibit poor overall survival. Among families of soluble human NKG2D ligands, the soluble human MHC I chain-related molecule (sMIC) was found to be elevated in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basher, Fahmin, Dhar, Payal, Wang, Xin, Wainwright, Derek A., Zhang, Bin, Sosman, Jeffrey, Ji, Zhe, Wu, Jennifer D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285527/ https://www.ncbi.nlm.nih.gov/pubmed/32517713 http://dx.doi.org/10.1186/s13045-020-00896-0

Ejemplares similares

Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation
por: Dhar, Payal, et al.
Publicado: (2021)

Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC(+) tumors respond to PD1/PD-L1 blockade therapy
por: Zhang, Jinyu, et al.
Publicado: (2019)

Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC
por: Basher, Fahmin, et al.
Publicado: (2015)

NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
por: Zhang, Jinyu, et al.
Publicado: (2015)

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
por: Zhang, Jingyu, et al.
Publicado: (2017)

Tumor-Derived Soluble MICA Obstructs the NKG2D Pathway to Restrain NK Cytotoxicity
por: Luo, Qizhi, et al.
Publicado: (2020)

Intracellular Sequestration of the NKG2D Ligand MIC B by Species F Adenovirus
por: Oliveira, Edson R. A., et al.
Publicado: (2021)

Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy
por: Peng, Peng, et al.
Publicado: (2022)

Colorectal cancer with Synchronous liver-limited Metastases: the protocol of an Inception Cohort study (CoSMIC)
por: Siriwardena, Ajith K, et al.
Publicado: (2017)

Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
por: Poznanski, Sophie M, et al.
Publicado: (2021)

NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
por: Murad, Shafiq, et al.
Publicado: (2022)

Genomic screening methodology not requiring barcoding: Single nucleotide polymorphism-based, mixed-cell screening (SMICS)
por: Zhang, Zhuwei, et al.
Publicado: (2023)

The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
por: Kaulfuss, Meike, et al.
Publicado: (2023)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

Potential of the NKG2D/NKG2DL Axis in NK Cell-Mediated Clearance of the HIV-1 Reservoir
por: Desimio, Maria G., et al.
Publicado: (2019)

NK Cell Plasticity in Cancer
por: Liu, Sizhe, et al.
Publicado: (2019)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Inhibitory NKG2A(+) and absent activating NKG2C(+) NK cell responses are associated with the development of EBV(+) lymphomas
por: Vietzen, Hannes, et al.
Publicado: (2023)

Unusual Presentation of Renal Medullary Carcinoma With Undiagnosed Sickle Cell Trait
por: Basher, Fahmin, et al.
Publicado: (2020)

Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors
por: Koch, Christine, et al.
Publicado: (2017)

Increased serum NKG2D-ligands and downregulation of NKG2D in peripheral blood NK cells of patients with major burns
por: Haik, Josef, et al.
Publicado: (2015)

Polyclonal Expansion of NKG2C(+) NK Cells in TAP-Deficient Patients
por: Béziat, Vivien, et al.
Publicado: (2015)

NKG2A is a NK cell exhaustion checkpoint for HCV persistence
por: Zhang, Chao, et al.
Publicado: (2019)

High Metabolic Function and Resilience of NKG2A-Educated NK Cells
por: Highton, Andrew J., et al.
Publicado: (2020)

Responsiveness to Influenza Vaccination Correlates with NKG2C-Expression on NK Cells
por: Riese, Peggy, et al.
Publicado: (2020)

Dissection of the NKG2C NK cell response against Puumala Orthohantavirus
por: Vietzen, Hannes, et al.
Publicado: (2021)

NK cells from COVID-19 positive patients exhibit enhanced cytotoxic activity upon NKG2A and KIR2DL1 blockade
por: Lee, Grace, et al.
Publicado: (2023)

PDL-1 Blockade Prevents T Cell Exhaustion, Inhibits Autophagy, and Promotes Clearance of Leishmania donovani
por: Habib, Samar, et al.
Publicado: (2018)

Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade
por: Wang, Chensu, et al.
Publicado: (2021)

NK Cell Priming From Endogenous Homeostatic Signals Is Modulated by CIS
por: Delconte, Rebecca B., et al.
Publicado: (2020)

A Role for NKG2D in NK Cell–Mediated Resistance to Poxvirus Disease
por: Fang, Min, et al.
Publicado: (2008)

Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory?
por: Della Chiesa, Mariella, et al.
Publicado: (2015)

NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML
por: Schlegel, Patrick, et al.
Publicado: (2015)

Endothelial cells express NKG2D ligands and desensitize antitumor NK responses
por: Thompson, Thornton W, et al.
Publicado: (2017)

Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
por: Melero, Ignacio, et al.
Publicado: (2023)

NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development
por: Jelenčić, Vedrana, et al.
Publicado: (2018)

Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade
por: Rossi, Alessandra, et al.
Publicado: (2020)

CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism
por: Medler, Juliane, et al.
Publicado: (2022)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

Soluble NKG2D ligands impair CD8(+) T cell antitumor function dependent of NKG2D downregulation in neuroblastoma
por: Zhang, Yi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7bor7uid057t558rk92164gh55